Nuvalent, Inc.(NUVL)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
NUVL Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Nuvalent, Inc. (NUVL), a Healthcare sector company. NUVL is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Nuvalent, Inc. reports net income of $-109.3M, free cash flow of $-92.4M. Top institutional holders of NUVL by reported 13-F value include DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), FMR, Paradigm Biocapital Advisors, based on the most recent SEC filings. NUVL trades on the Nasdaq exchange and files with the SEC under CIK 1861560. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NUVL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Nuvalent, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-109.3M
Free Cash Flow
Q1 2026
$-92.4M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-63.1% YoYOperating Income
-47.8% YoYEPS (Diluted)
-48.9% YoYTotal Assets
+23.7% YoYOp. Cash Flow
-48.7% YoY| Metric | FY 2025 | FY 2024 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Net Income | $-425.4M -63.1% | $-260.8M -218.6% | $-81.9M -76.6% | $-46.3M -218.3% | $-14.6M | — |
| Operating Income | $-414.3M -47.8% | $-280.4M -225.6% | $-86.1M -87.9% | $-45.8M -171.0% | $-16.9M | — |
| EPS (Diluted) | $-5.85 -48.9% | $-3.93 -138.2% | $-1.65 +22.5% | $-2.13 +58.1% | $-5.08 | — |
| Total Assets | $1.41B +23.7% | $1.14B +136.7% | $482.5M +64.2% | $293.8M +2659.9% | $10.6M | — |
| Operating Cash Flow | $-275.2M -48.7% | $-185.1M -184.8% | $-65.0M -62.4% | $-40.0M -167.6% | $-14.9M | — |
Get alerted when NUVL's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Nuvalent, Inc. including:
Top Institutional Holders of NUVL
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$1.8B17,248,450 shFMR LLC
$950.2M9,274,959 shParadigm Biocapital Advisors LP
$545.5M5,324,433 shBlackRock, Inc.
$494.3M4,824,785 shRA CAPITAL MANAGEMENT, L.P.
$259.6M2,534,145 shVANGUARD PORTFOLIO MANAGEMENT LLC
$256.2M2,500,907 shWELLINGTON MANAGEMENT GROUP LLP
$253.1M2,470,491 shVANGUARD CAPITAL MANAGEMENT LLC
$248.8M2,428,488 shSTATE STREET CORP
$208.6M2,035,831 shPolar Capital Holdings Plc
$187.6M1,831,253 sh
| Fund | Value | Shares |
|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | $1.8B | 17,248,450 |
| FMR LLC | $950.2M | 9,274,959 |
| Paradigm Biocapital Advisors LP | $545.5M | 5,324,433 |
| BlackRock, Inc. | $494.3M | 4,824,785 |
| RA CAPITAL MANAGEMENT, L.P. | $259.6M | 2,534,145 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $256.2M | 2,500,907 |
| WELLINGTON MANAGEMENT GROUP LLP | $253.1M | 2,470,491 |
| VANGUARD CAPITAL MANAGEMENT LLC | $248.8M | 2,428,488 |
| STATE STREET CORP | $208.6M | 2,035,831 |
| Polar Capital Holdings Plc | $187.6M | 1,831,253 |
More Healthcare Companies
View all Healthcare →Put NUVL on your watchlist
Track score changes the day Nuvalent, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NUVL a good stock to buy?
13F Pro's AI-powered analysis of Nuvalent, Inc. (NUVL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NUVL are available on the NUVL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own NUVL?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NUVL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Nuvalent, Inc.'s investment landscape.